Investing Center Preview – Manage your investments and watch your net worth grow.
JNJ:NYSE – Large Cap Stock (Drug Manufacturers)
Johnson & Johnson – JNJ Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
178.91 | 0.15 (+0.08%) | 140.68 - 181.16 | 1.7 million (Below Avg) |
Market data as of 12:59PM 09/05/25. Quotes are delayed by at least 15 min.
Overview - JNJ
Open | 177.50 |
---|---|
Previous Close | 178.76 |
Day's Range | 177.00 - 179.51 |
Market Cap | 430.9B |
Avg Volume (10 Day) | 7.6M |
Price/Earnings (Trailing 12 Mo.) | 19.1x |
Earnings Per Share (Trailing 12 Mo.) | 3.405 |
Dividend Yield | 1.30 (2.91%) |
One-Click Scorecard - JNJ


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Fail |
---|---|
Avoids excess debt? | Pass |
Converting sales to profits? | Fail |
Shareholder's money handled rationally? | Pass |
Increased shareholder value? | Fail |
Consistently increased owner earnings? | Pass |
Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Pass |
---|---|
Room to increase dividends? | Fail |
Increased earnings over time? | Pass |
Borrows within reasonable limits? | Pass |
Stock is undervalued? | Fail |
Have investors caught on? | Fail |
Has support of institutional investors? | Pass |
Has sufficient liquidity? | Pass |
Latest Headlines - JNJ
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
Business Wire - Wednesday 09/03/2025 4:29 PM ET
Johnson & Johnson Unveils Results from the VARIPURE Substudy of SECURE, a Real-World Study on VARIPULSE™ Platform, at 2025 European Society of Cardiology (ESC) Congress
PR Newswire - Tuesday 09/02/2025 8:00 AM ET
New Data from the DanGer Shock Randomized Control Trial, Published in The New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump
PR Newswire - Sunday 08/31/2025 12:15 PM ET
AMDR Applauds Federal Court Decision to Bar Johnson & Johnson’s Biosense Webster Unit from Further Violation of Anti-Trust Laws in a Win for Hospitals, Patients, and the Environment
Business Wire - Thursday 08/28/2025 8:00 AM ET
Industry Position - JNJ
JNJ | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 4.30% | |
Net Income Growth (1yr) | -59.99% | |
Total Debt/Equity | 0.65 | |
LT Debt/Equity | 0.50 | |
Earnings Yield | 5.25% | |
Price/Sales | 4.77 |
Competitors - JNJ
Company | Last | Change |
---|---|---|
72.47 | +5.56% | |
-- | -- | |
AbbVie Inc | 211.77 | -0.58% |
1614.00 | -0.68% | |
5124.00 | -0.66% |
Data is delayed by at least 15 min.